Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Vladimir Vexler"'
Autor:
Sheng Yao, Sruthi Ravindranathan, Theresa LaVallee, Sanjay D Khare, Narendiran Rajasekaran, Patricia Keegan, Xiaoguang Wang, Daniel J Chin, Su-Yi Tseng, Scott Klakamp, Kate Widmann, Varun Kapoor, Vladimir Vexler
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/be6e03e567ca486f9b68f511ad6c41df
Autor:
Francesca Civoli, Barbara Finck, Helen Tang, Jennifer Hodge, Hillary O’Kelly, Vladimir Vexler
Publikováno v:
Advances in Therapy. 39:1230-1246
Biologic therapeutics can trigger immune responses in patients. As part of the totality of evidence that is required for regulatory approval of biosimilars, immunogenicity similarity must be assessed in the clinical programs. Pegfilgrastim-cbqv (UDEN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ba756d9d42a0504515dd64f1aa9943c
https://doi.org/10.1007/s12325-021-02024-x
https://doi.org/10.1007/s12325-021-02024-x
Autor:
Thierry Sornasse, Stephen Hartman, Lyubov Efros, Vladimir Vexler, Bishu Ganguly, Archana B. Thakur, Joanna M. Xiong, Paul R. Hinton, Balaji Balasa, James P Sheridan, Randy R. Robinson, Brian Schmidt
Publikováno v:
mAbs
The CD25-binding antibody daclizumab high-yield process (DAC HYP) is an interleukin (IL)-2 signal modulating antibody that shares primary amino acid sequence and CD25 binding affinity with Zenapax®, a distinct form of daclizumab, which was approved
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7dbe63bfbb3319e44289c735f69665f3
https://doi.org/10.1080/19420862.2016.1207031
https://doi.org/10.1080/19420862.2016.1207031
Autor:
Rosario Garrido, Chandrasena Pamulapati, Stefan Ries, Vladimir Vexler, Sandhya Bohini, Michael Schraeml, Changhua Ji, Klaus Klumpp, Li Yu, Hans Peter Grimm, Michael Brandt, Usha Singh, Han Ma, Priya Sriraman
Publikováno v:
mAbs. 5:776-786
CD81 is an essential receptor for hepatitis C virus (HCV). K21 is a novel high affinity anti-CD81 antibody with potent broad spectrum anti-HCV activity in vitro. The pharmacokinetics (PK), pharmacodynamics and liver distribution of K21 were character
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6108b94b4577aed28d93b96d16322198
https://doi.org/10.4161/mabs.25642
https://doi.org/10.4161/mabs.25642
Autor:
James Sheridan, MT Tang, M McClellan, Lyubov Efros, Vladimir Vexler, D Shi, Ying Zhang, Bibi Bielekova
Publikováno v:
Multiple Sclerosis Journal. 20:156-164
Daclizumab is a humanized monoclonal antibody that prevents interleukin-2 (IL-2) binding to CD25, blocking IL-2 signaling by cells that require high-affinity IL-2 receptors to mediate IL-2 signaling. The phase 2a CHOICE study evaluating daclizumab as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcd130cb8a1fd57813e597420d8e55fe
https://doi.org/10.1177/1352458513494488
https://doi.org/10.1177/1352458513494488
Autor:
Jia Shi, Jeffrey Harris, Katherine Riester, Ying Zhang, Lyubov Efros, Vladimir Vexler, Jacob Elkins, Meina T Tang, James Sheridan
Publikováno v:
Multiple Sclerosis Journal. 17:1441-1448
Objective: The objective of this study was to evaluate whether interleukin-2 (IL-2) receptor expression on CD56bright natural killer (NK) cells predicted CD56bright NK cell expansion and therapeutic response to daclizumab (DAC) in multiple sclerosis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::510c7feabefd172422e8e352b97dd85c
https://doi.org/10.1177/1352458511414755
https://doi.org/10.1177/1352458511414755
Autor:
William W, Busse, Elliot, Israel, Harold S, Nelson, James W, Baker, B Lauren, Charous, Donald Y, Young, Vladimir, Vexler, Richard S, Shames, S, Weakley
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 178:1002-1008
Airway inflammation in asthma is associated with increased activated CD25(+) T cells, IL-2, and soluble IL-2 receptors (IL-2Rs).A randomized, double-blinded, placebo-controlled study was used to evaluate the safety and efficacy of daclizumab, a human
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::405ef77ca2f10733e0b193c7f5bb4cc7
https://doi.org/10.1164/rccm.200708-1200oc
https://doi.org/10.1164/rccm.200708-1200oc
Autor:
Shankar Kumar, Gao Liu, Anne van Abbema, Susan Rhodes, Vladimir Vexler, Amulya Nanisetti, Benny P. Shum, John D. Shaughnessy, Melanie Wong, Naoya Tsurushita, Fenghuang Zhan, Shihao Chen, Daniel E. H. Afar, Aparna Draksharapu, Audie Rice, Mahrukh Huseni, David M. W. Powers, Bart Barlogie, Yin Zhang, Balaji Balasa, Marna Williams, Franklin Fuh, Mohamad A. Hussein, Eric D. Hsi, Roxanne Steinle, Susann Szmania, Myles B.C. Dillon, Frits van Rhee
Publikováno v:
Clinical Cancer Research. 14:2775-2784
Purpose: We generated a humanized antibody, HuLuc63, which specifically targets CS1 (CCND3 subset 1, CRACC, and SLAMF7), a cell surface glycoprotein not previously associated with multiple myeloma. To explore the therapeutic potential of HuLuc63 in m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a51201b042fb124cd1c452c079014fcf
https://doi.org/10.1158/1078-0432.ccr-07-4246
https://doi.org/10.1158/1078-0432.ccr-07-4246
Autor:
Jacky Woo, Vladimir Vexler
Publikováno v:
Drug Discovery Today: Therapeutic Strategies. 3:353-360
Recent advances in understanding the immune-mediated mechanisms underlying the pathophysiology of ulcerative colitis (UC) identified a variety of novel targets. The monoclonal antibodies that either recognize epitopes on immune-competent cells, or ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::154ce565a25b88051cd874b8856737cf
https://doi.org/10.1016/j.ddstr.2006.07.002
https://doi.org/10.1016/j.ddstr.2006.07.002
Publikováno v:
Neurological Research. 23:72-78
Neutrophils are known to mediate injury in acute ischemic stroke especially during reperfusion. Migration of neutrophils into regions of ischemic injury involves binding to the endothelial cells via interactions with various adhesion molecules. One a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ba610be18fee66e3af4d1d2e6e425c9
https://doi.org/10.1179/016164101101198154
https://doi.org/10.1179/016164101101198154